Serum sCD14 may serve as a biomarker to predict worsening liver inflammation and evaluate therapeutic effects in NAFLD.
sCD14 may mark NAFLD inflammation severity; hypothesis-generating and requires prospective validation before clinical use.
We found that serum sCD14 levels increased significantly with increasing liver inflammation grade in patients with NAFLD, reflecting increased hepatic CD14 expression. Serum sCD14 is a promising tool to predict the worsening of liver inflammation, and may offer a potential biomarker for evaluation of therapeutic effects in NAFLD.
No takes yet. Share an insight, caveat, or question.
Ogawa et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: